ep
debt total capit
top bottom reaffirm guidanc
bd report solid perform revenu earn ahead street
manag re-affirmed guidanc albeit weight upbeat
product pipelin year continu believ bd pois beat rais
estim cours accordingli rais multipl
ep estim
result bd report cc revenu growth pjc
report street medic revenu growth cc
report street estim
cc growth forecast life scienc revenu growth cc report
quarter street estim intervent revenu
growth cc street estim adj gross
margin increas bp cc y/i estim opex spend
forecast adj ep
street estim estim
busi updat quarter strength driven medic segment
strong perform s/china revenu bd paid
debt quarter drop leverag target dec
tax rate lower expect although revers
manag maintain rang bd continu gross
margin expans bp cc y/i result bard higher margin profil
on-going cost control initi bd expect cost synergi bard
driven suppli chain procur manag note
materi impact paclitaxel studi releas decemb better
anecdot dilig
guidanc manag re-affirmed guidanc compar cc revenu growth
guidanc report includ unfavor fx impact
ep growth guidanc report compar cc
manag reiter compar cc growth medic
life scienc intervent
stock anoth solid quarter bd reiter beat
rais thesi accordingli rais ep multipl ep
price target rise
competit new product execut foreign currenc acquisit integr
becton dickinson diversifi medic technolog compani
actual may match report figur due restat associ divestitur complet end
ep includ sbc exclud item
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
becton dickinson compani
page
million except share per share data
updat
good sold
provis incom tax
good sold
good sold
current disclosur inform compani locat
